Evotec partner Kazia Therapeutics announces full regulatory approval for Phase I study of EVT801


Sydney, Australia, 02 September 2021:
Evotec partner Kazia Therapeutics Limited (“Kazia”, ASX: KZA; NASDAQ: KZIA) today announced that the planned phase I study for EVT801 has received full approval from L’Agence Nationale de Sécurité du Médicament et des Produits de Santé (“ANSM”), the French regulatory agency. The study is expected to open to recruitment by the end of CY2021.

Evotec and Kazia entered into both a licensing and master service agreement in April 2021. Under the contract, Evotec grants Kazia an exclusive worldwide license for research, development and commercialisation of Evotec’s oncology project EVT801, a small molecule inhibitor of the lymphatic growth factor receptor VEGFR3, originally developed within Evotec’s partnership with Sanofi.

Kazia CEO, Dr James Garner, commented: “since concluding our license agreement with Evotec in April, we have made exceptionally swift progress in bringing EVT801 to the clinic. We have been grateful for the exceptional efforts of the Evotec team, working closely with Kazia colleagues to drive the project forward. The study that we have designed is highly innovative, which befits the rich potential of EVT801, and we look forward to commencing recruitment in the near future.”

For further information, please follow this link to the full version of the press release from Kazia Therapeutics.